Adinoff, B., NIH, Clinical Trials Network: North Texas Node, $877,141; Barber, R., NIH/UTHSC Houston, H. pylori Infection in Hispanic Children: Immune Response Pathway SNP Patterns, $73,634; Brekken, R., NSF, 2008 NSF Graduate Research Fellowship Award, $30,000 (Williams, K., fellow); Brown, K., NIH/Duke Univ., Development of Novel Therapies of NIDDM: CORE B: Gene Targeting Core, $55,643; Buchanan, G., HRSA, Health Care and Other Facilities, $478,527.
Buchanan, G., NIH, Southwestern Comprehensive Sickle Cell Center, $229,823; Burgess, S., NIH/Duke Univ., Development of Novel Therapies of NIDDM: CORE C: NMR-Based Flux Analysis, $67,121; Carroll, T., NIH, The Role of Wnt Signaling in Kidney Tubule Formation, $200,000; Chen, D., NIH/Univ. of Calif., Structural Cell Biology of DNA Repair Machines, $63,000; Cleaver, O., NIH, Endothelial Signals During Organogenesis, $181,300.
Clegg, D., NIH/Univ. of Cincinnati, Insulin and CNS Control of Body Weight and Food Intake, $59,954; Cobb, M., NIH, Cell and Molecular Biology Training Program, $367,536; Cobb, M., NIH, Insulin-Regulated MAP Kinase Pathways, $277,534; Corey, D., NIH, Recognition of Chromosomal DNA by Double-Stranded RNA, $190,000; Darnell, C., NIH/Case Western Reserve Univ., Pediatric Off-Patient Study Center for Lorazepam Sedations, $2,972.
Diaz-Arrastia, R., NIH/Univ. of Calif., San Francisco, Domain Specific Tasks of Executive Function, $50,644; Diaz-Arrastia, R., NIH/Columbia Univ. Med. Ctr., Genetic Consortium for Late Onset Alzheimer’s Disease, $97,332; Diaz-Arrastia, R., DOE, North Texas Traumatic Brain Injury Model System, $341,547; Dries, D., NIH, Gamma-Secretase: The First Enzymology-Based Study of Intramembrane Proteolysis, $49,646; Falck, J., NIH/Vanderbilt Univ. Med. Ctr., Role of Icosanoids in Renal Function: Core C., $88,027.
Falck, J., NIH/New York Med. Coll., Hormonal Regulation of Blood Pressure, $74,041; Fischer, A., NIH, Novel Strategies for Aerosolized AAV Gene Therapy, $118,750; Freeman, A., CDC, HIV Training Through Prevention Training Centers, $201,614; Freeman, A., CDC, CBA to Improve the Delivery and Effectiveness of HIV Prevention Interventions, $381,450; Garcia-Martinez, J.V., NIH, Nef Function, $42,250.
Gao, J., NIH, Mfe204-Loaded Polymer Micelles as Ultra-Sensitive MR Mo, $278,728; Garg, A., NIH, Novel Therapies for Metabolic Complications in Patients with Lipodystrophies, $214,106; Garner, H., NIH, Duplicate Article/Plagiarism Discovery, $183,036; Ghose, S., NIH, A Gene Environment Interaction in Schizophrenia, $155,300; Goldstein, J., NIH, Molecular Basis of Cholesterol Metabolism, $3,400,901.
Hill, J., NIH, Training in Cardiovascular Research, $846,521; Hoopman, T., NIH, Gene Expression by Moraxella Catarrhalis in Vivo, $100,000; Hughes, C., NIH, Exercise Treatment for Depressed Youth, $144,360; Idris, A., NIH, Circulatory Compromise Opportunities to Improve Outcome, $243,118; Jarrett, R., NIH, Prophylactric Cognitive Therapy for Depression, $196,628.
Jiang, Y., NIH, Mechanism of Ligand Gating in Potassium Channels, $170,673; Jiang, Y., NIH, Molecular Mechanisms of Caton Channel Selectivity, $175,000; Kliewer, S., NIH/Van Andel Research Inst., Structure Genomics of Orphan Nuclear Receptors, $14,648; Kodadek, T., NIH/Duke Univ. Med. Ctr., Development of Novel Therapies for NIDDM: Project 3: Manipulation of Gene Expression with Small Molecules, $201,086; Kowalske, K., DOE, North Texas Burn Rehabilitation Model System, $287,698.
Lister, G., NIH, National Children’s Study, $468,658; MacDonald, R., NIH/ Vanderbilt Univ. Med. Ctr., Signal Activated Sentinels for Beta-Cell Development and Regeneration, $11,000; McKnight, S., NIH, A Concerted Chemical, Biophysical and Molecular Biological Attack of Intracellular Pathways Relevant to Cancer, $2,110,104; Mahendroo, M., NIH, Molecular Mechanisms of Parturition, $157,962; Malloy, C., NIH, Southwestern NMR Center for In Vivo Metabolism, $666,108.
Martinez, E., NIH, Characterization of Small Molecule Inhibitors of HDACs and DNMTs, $126,478; Mohan, C., NIH, NIAMS: CORT – Genetic Dissection of SLE – From Mouse to Man, $1,098,023; Muallem, S., NIH, Hormone Regulation of (Ca2 )I in Pancreatic Acinar Cells, $218,366; Niederkorn, J., NIH, Immunobiology of Corneal Allografts, $220,500; Niederkorn, J., NIH, Immunobiology of Corneal Allografts, $30,747 (Supplement).
Olson, E., NIH/Yale Univ., Pediatric Physician Scientist Program Award, $100,500 (Hatley, M., fellow); Parada, L., DOD/Univ. of Calif., San Francisco, Preclinical Mouse Models of Neurofibromatosis, $213,226; Partch, C., NIH, Molecular Basis of Selectivity for Coactivator Recruitment by ARNT PAS Domains, $49,646; Ramilo, O., Texas Dept. of State Health Services, Human-Immunodeficiency Virus: Perinatal Prevention, $93,174; Ramilo, O., HRSA, EMSC Targeted Issue Grants, $167,190.
Ranganathan, R., NIH, Mechanistic Analysis of Dynamic Scaffolding in a Cellular Signaling Network, $220,500; Rivera, F., NIH, Genetics of Innate Immune Response After Burn Trauma, $110,750; Robertson, D., NIH, P63/ IGFBP2/BCL2 Control of Corneal Epithelial Homeostasis, $175,000; Robertson, D., NIH, The Role of BCL-2 in Corneal Epithelial Cell Shedding, $93,905; Rogers, Z., NIH, Baby Hug Study, $790,585.
Roland, P., NIH/Duke Clin. Research Inst., CHEER Network: Creating Health Care Excellence, $10,997; Rosenberg, R., NIH/Univ. of Wash., National Alzheimer’s Coordinating Center, $18,408; Scherer, P., JDRF/Duke Univ. Med. Ctr., Novel Pathways to Expansion of Functional Beta Cell Mass, $50,000; Scheuermann, R., NIH/Northrop Grumman, Bioinformatics Integration Support Contract, $578,954; Shay, J., U.S. Army, Manipulating Telomere Overhang Processing to Develop Novel Approaches for Breast Cancer Treatment, $30,000 (Chow, T., fellow).
Shay, J., NASA, Risk Assessment of Space Radiation-Enhanced Colon Tumorigenesis, $233,073; Shay, J., U.S. Army, Structural and Dynamic Elucidation of Telomeric Ends: A Novel Approach to Breast Cancer Therapeutics, $30,000 (Mak, S., fellow); Sherry, D., NIH/Duke Univ., Development of Novel Therapies for NIDDM, $260,932; Sinha, S., NIH, Molecular Mechanism by Which Gamma-Herpesviruses Evade Authophagy, $150,000; Smith, S., NIH, Pathogenesis of Exercise Pressor Reflex Dysfunction in Hypertension, $26,922 (Leal, A., fellow).
Smith, D., NIH, Role of the T1 Neuronal Circuit in Pheromone Behaviors, $100,000; Snell, W., NIH, Gamete Membrane Adhesion and Fusion During Fertilization, $175,000; Snell, W., NIH, Cell Surface Recognition and Cell Interactions, $75,855; Story, M., NIH/UT Dallas, Gamma Globin Induction: Molecular and Cell-Based Strategies, $41,923; Tamminga, C., NIH/Wayne State Univ., Bipolar-Schizophrenia Network for Intermediate Phenotypes, $38,500.
Toto, R., NIH, Improving Outcomes in Diabetic Nephropathy, $21,000; Trivedi, J., NIH/Kansas Univ. Med. Center, Phase II Therapeutic Trial of Mexiletine, $22,014; Vernino, S., NIH/Mayo Clinic Legal Dept., Autonomic Disorders Program Project, $85,073; Victor, R., NIH, Cocaine and Sympathetic Nerve Activity in Humans, $185,843; Ward, E.S., NIH/UT Dallas, High Accuracy Quantum Dot Tracking in Live Cells, $15,924.
Yu, H., NIH, Protection of Centromeric Cohesion by Bub1 and Sgo 1, $27,704; Zhao, Y., NIH, Systematic Screening for New Histone Marks, $538,307; Zimmern, P., NIH, Trial of Mid-Urethral Slings, $224,564.
Altschuler, S., Rita Allen Fndtn., Predicting Drug Sensitivity and Gene Expression From Single-Cell Cancer Phenotypes, $110,000; De Brabander, J., Texas Ignition Fund, Synthesis and in Vitro/in Vivo Evaluation of the Vascular ATPase Inhibitor Palmerolide as a Novel Anticancer Agent, $50,000; DiMaio, J.M., Texas Ignition Fund, Integrated Patient Bed System, $25,000; Garner, H., Texas Ignition Fund, Xanapath, $10,000; King, R., NIH/UT Dallas, Neuroimaging of Dedifferentiation and Memory Across the Lifespan, $85,000.
King, R., AHA, Effect of Simulation Training on ACLS Skills Performance, $45,450; Lin, W., Robert Packard Center for ALS Research at Johns Hopkins, Neuromuscular Synaptic Degeneration in Motoneuron Diseases, $85,000; Liu, Z., NKF, Role of WNK 1 in Renal K Secretion, $40,000; Lu, R.Q., Brain Tumor Society, Mitotic Olig2-Expressing Cells in Glioma Formation, $100,000; McPhaul, M., Doris Duke Charitable Fndtn., Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center, $181,338.
Mehdi, U., NKF, Study of Urinary Proteomes in Diabetic Nephropathy, $40,000; Mohan, C., Arthritis Fndtn., Controlling Autoimmunity by Modulation of Dyregulated Signaling Pathways, $79,167 (Liu, K., fellow); Mohan, C., Arthritis Fndtn., DC: B-Cell Liaison in Lupus, $50,000 (Zhu, J., fellow); Phillips M., Medicines for Malaria Venture, Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Testing Malaria, $186,269.
Raj, G., Prostate Cancer Fndtn., Nanoparticle-Based Molecular Targeting of the Androgen Receptor and its Co-Activator in Metastatic Prostate Cancer, $75,000; Sharifi, N., Coulter Enterprises, The Role of SOD2 Down Regulation in Castration-Resistant Prostate Cancer and Potential Implications for Therapy With Antioxidants, $75,000; Vitetta, E., Bill & Melinda Gates Fndtn., A New Platform for Making Effective Vaccines Against Pathogens That Cause Infectious Diseases, $100,000; Xie, S., Arthritis Fndtn., Genetics of B-Cell Tolerance, $79,167.
Pharmaceutical studies, dollar amounts not available
Arko, F., Pressure and Imaging Using the CardiosMEMS EndoSure Sensor for Long-Term Follow-up After EVAR With Standard Surveillance (Prospective Registry); Chitnis, S., Prospective, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Trial With an Open-Label Extension Period to Investigate the Efficacy and Safety of Study Drug in the Treatment of Blepharospasm Phase 3; Khera, A., A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Study Drug on Cardiovascular Risk in Stable CHD Patients With a Documented Recent Acute Coronary Syndrome.
Lee, W., An Open Label, Proof-of-Concept, Dose-Escalation Study to Evaluate the Effects of Study Drug on Hepatitis C Viral Load in Patients With Chronic Hepatitis, Genotype 1 and Its Correlation with Lipid-Level; Seikaly, M., A Multicenter, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Weeks Study Drug Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis; Whitson, J., A Multicenter, Masked Evaluation of Ocular Surface Tolerability Associated With Bimatoprost 0.03 Percent, Travoprost 0.004 Percent (BAK-free) or Latanoprost 0.005 Percent Therapy in Patients With Glaucoma or Ocular Hypertension.